Hillsdale Investment Management Inc. Makes New $545,000 Investment in Bruker Co. (NASDAQ:BRKR)

Hillsdale Investment Management Inc. acquired a new position in shares of Bruker Co. (NASDAQ:BRKR) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,900 shares of the medical research company’s stock, valued at approximately $545,000.

A number of other institutional investors have also modified their holdings of BRKR. Legal & General Group Plc increased its holdings in Bruker by 13.7% during the fourth quarter. Legal & General Group Plc now owns 47,736 shares of the medical research company’s stock valued at $1,421,000 after buying an additional 5,745 shares during the period. Dimensional Fund Advisors LP grew its holdings in Bruker by 4.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,013,763 shares of the medical research company’s stock worth $30,178,000 after purchasing an additional 46,244 shares during the last quarter. Virtu Financial LLC purchased a new position in Bruker in the first quarter worth $285,000. Nisa Investment Advisors LLC grew its holdings in Bruker by 10.6% in the first quarter. Nisa Investment Advisors LLC now owns 14,298 shares of the medical research company’s stock worth $550,000 after purchasing an additional 1,372 shares during the last quarter. Finally, Strs Ohio grew its holdings in Bruker by 5.3% in the first quarter. Strs Ohio now owns 10,685 shares of the medical research company’s stock worth $410,000 after purchasing an additional 537 shares during the last quarter. 66.44% of the stock is currently owned by institutional investors.

In other Bruker news, CEO Frank H. Laukien sold 400,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $41.48, for a total value of $16,592,000.00. Following the completion of the transaction, the chief executive officer now owns 37,991,030 shares in the company, valued at $1,575,867,924.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 26.50% of the company’s stock.

Several equities analysts have issued reports on the stock. BidaskClub lowered shares of Bruker from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. ValuEngine lowered shares of Bruker from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Jefferies Financial Group lifted their price target on shares of Bruker from $45.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, June 21st. Needham & Company LLC set a $57.00 price target on shares of Bruker and gave the stock a “strong-buy” rating in a report on Monday, June 24th. Finally, Leerink Swann raised shares of Bruker from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $48.18.

NASDAQ BRKR traded down $0.04 on Tuesday, reaching $41.41. 890 shares of the company’s stock traded hands, compared to its average volume of 1,127,906. The firm has a market cap of $6.41 billion, a price-to-earnings ratio of 29.61, a P/E/G ratio of 2.06 and a beta of 1.30. The stock has a 50 day moving average price of $46.35 and a 200-day moving average price of $41.87. Bruker Co. has a fifty-two week low of $26.10 and a fifty-two week high of $51.41. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.27 and a current ratio of 2.19.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, August 1st. The medical research company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.02. The company had revenue of $490.20 million during the quarter, compared to the consensus estimate of $477.70 million. Bruker had a net margin of 9.57% and a return on equity of 27.10%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.25 earnings per share. As a group, equities research analysts anticipate that Bruker Co. will post 1.61 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 20th. Shareholders of record on Tuesday, September 3rd will be given a $0.04 dividend. The ex-dividend date of this dividend is Friday, August 30th. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.39%. Bruker’s dividend payout ratio (DPR) is currently 11.43%.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Featured Story: How is a buy-side analyst different from a sell-side analyst?

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.